Related Experiment Videos

Structural basis for Chk1 inhibition by UCN-01

Baoguang Zhao1, Michael J Bower, Patrick J McDevitt

  • 1Department of Structural Biology, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA.

Insights

The crystal structure reveals how UCN-01, a Chk1 inhibitor, binds to the Chk1 kinase domain. This provides insight into the DNA damage response and cell cycle control mechanisms.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Checkpoint kinase 1 (Chk1) is crucial for the DNA damage response and G(2)/M cell cycle control.
  • UCN-01 (7-hydroxystaurosporine) is a potent Chk1 inhibitor currently in clinical trials, known to abrogate DNA damage-induced G(2)/M checkpoints.

Purpose of the Study:

  • To elucidate the structural basis of Chk1 inhibition by UCN-01.
  • To understand the molecular interactions responsible for UCN-01's potency and selectivity.

Main Methods:

  • X-ray crystallography was employed to determine the crystal structure of the Chk1 kinase domain.
  • Structures were solved for Chk1 in complex with UCN-01, staurosporine, and SB-218078.

Main Results:

  • All three inhibitors (UCN-01, staurosporine, SB-218078) bind within the ATP-binding pocket of Chk1 with minimal conformational changes.
  • The selectivity of UCN-01 for Chk1 over cyclin-dependent kinases is attributed to a hydroxyl group in its lactam moiety interacting with the ATP-binding pocket.
  • Detailed hydrophobic and hydrogen-bonding interactions between UCN-01 and the Chk1 kinase domain were identified.

Conclusions:

  • The determined crystal structures provide a detailed molecular understanding of Chk1 inhibition by UCN-01.
  • The structural insights support the observed potency and selectivity of UCN-01 as a Chk1 inhibitor.
  • This structural information can aid in the design of novel Chk1-targeting therapeutics for cancer treatment.

Related Concept Videos